<DOC>
	<DOCNO>NCT00087529</DOCNO>
	<brief_summary>This Phase II/III , randomize , double-blind , parallel group , placebo control , multicenter study evaluate safety efficacy rituximab adult PPMS . The study enroll approximately 435 subject 60 site United States Canada .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Rituximab Adults With Primary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Definitive diagnosis PPMS Disease duration ≥ 1 year EDSS baseline 2.0 6.5 point , inclusive Score ≥ 2.0 Functional Systems ( FS ) scale pyramidal system gait due low extremity finding Presence least one follow CSF specimen obtain screen period analyze central laboratory result CSF sample obtain previous 24 month : For subject reproductive potential ( male female ) , use reliable mean contraception ( e.g. , hormonal contraceptive , patch , vaginal ring , intrauterine device , physical barrier ) study treatment 1 year follow last dose study drug Pregnancy lactation Incompatibility MRI Lack peripheral venous access History severe allergic anaphylactic reaction humanize murine monoclonal antibody Known active bacterial , viral , fungal , mycobacterial , infection ( include atypical mycobacterial disease , exclude fungal infection nail bed recurrent herpes zoster simplex infection ) major episode infection require hospitalization treatment IV antibiotic within 30 day prior screen oral antibiotic within 14 day prior screen History presence recurrent chronic infection ( e.g. , hepatitis B C , HIV , syphilis ) History cancer , include solid tumor hematologic malignancy ( except resect fully resolve cutaneous basal cell squamous cell carcinoma ) History alcohol drug abuse within 6 month prior screen History currently active primary secondary immunodeficiency Significant cardiac pulmonary disease ( include obstructive pulmonary disease ) Presence significant , uncontrolled cardiovascular , pulmonary , renal , hepatic , endocrine , gastrointestinal disease might interfere subject 's ability participate complete approximately 2.5 year study participation History presence MS relapse exacerbation History presence vascular disease potentially affect brain spinal cord ( e.g. , stroke , transient ischemic attack , carotid stenosis , aortic aneurysm , intracranial aneurysm , hemorrhage , arteriovenous malformation ) History presence myelopathy due spinal cord compression disk vertebral disease History severe , clinically significant central nervous system trauma ( e.g. , cerebral contusion , spinal cord compression ) History intracranial intraspinal tumor ( e.g. , meningioma , glioma ) History presence potential metabolic cause myelopathy encephalopathy ( e.g. , vitamin B12 deficiency , thyroid abnormality ) History presence infectious cause myelopathy ( e.g. , syphilis , Lyme disease , human Tcell lymphotropic virus type 1 [ HTLV1 ] , herpes zoster myelopathy ) History genetically inherit progressive CNS degenerative disorder ( e.g. , Xlinked adrenoleukodystrophy , hereditary spastic paraparesis ) Neuromyelitis optica History presence systemic autoimmune disorder potentially cause progressive neurologic disease ( e.g. , lupus , antiphospholipid antibody syndrome , Sj�gren syndrome , Beh�et disease ) History presence sarcoidosis Previous treatment rituximab ( MabThera ( R ) /Rituxan ( R ) ) Previous treatment lymphocytedepleting therapy ( e.g. , cyclophosphamide , Campath ( R ) , antiCD4 , cladribine , total body irradiation , bone marrow transplantation ) , except mitoxantrone , use 12 month prior randomization Treatment investigational agent within 90 day 5 halflives investigational drug ( whichever longer ) prior randomization Receipt live vaccine within 30 day prior randomization Systemic corticosteroid therapy within 30 day prior randomization Treatment IFN &amp; # x3B2 ; , glatiramer acetate , IVIg , plasmapheresis within 60 day prior randomization Treatment nonlymphocytedepleting immunosuppressive therapy ( e.g. , azathioprine , mycophenolate mofetil [ MMF ] , cyclosporine ) within 90 day prior randomization Statins hormone replacement therapy start within 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>PPMS</keyword>
	<keyword>Primary progressive MS</keyword>
	<keyword>Primary progressive multiple sclerosis</keyword>
	<keyword>Rituxan</keyword>
	<keyword>MS</keyword>
</DOC>